Skip to main content

Innovative Medicines Initiative project - eTox


Drug development necessitates running in vivo toxicological studies for the assessment of potential untoward side effects. Toxicities may often limit the use of medicines, and sometimes prevent molecules to become drugs. Early selection of chemicals with a low probability of being toxic will improve the whole process, taking less time and resources, including the use of animals. Hence, early in silico prediction of in vivo toxicological results would increase the efficiency of the drug development process and reduce the number of animals to be used in preclinical studies.


The eTOX project aims to develop innovative methodological strategies and novel software tools to better predict the toxicological profiles of new molecular entities in early stages of the drug development pipeline. This is planned to be achieved by sharing and jointly exploiting legacy reports of toxicological studies from participating pharmaceutical companies The project will coordinate the efforts of specialists from industry and academia in the wide scope of disciplines that are required for a more reliable modelling of the complex relationships existing between molecular and in vitro information and the in vivo toxicity outcomes of drugs. The proposed strategy includes a synergetic integration of innovative approaches in the following areas:


  • Data sharing of previously unaccessible high quality data from toxicity legacy reports of the pharma companies.
  • Database building and management, including procedures and tools for protecting sensitive data.
  • Ontology and text mining techniques, with the purpose of facilitating knowledge extraction from legacy preclinical reports and biomedical literature.
  • Chemistry and structure-based approaches for the molecular description of the studied compounds, as well as of their interactions with the anti-targets responsible for the secondary pharmacologies.
  • Prediction of DMPK (Drug Metabolism and Pharmacokinetics) features since they are often related to the toxicological events.
  • Systems biology approaches in order to cope with the complex biological mechanisms which govern in vivo toxicological events.
  • Computational genomics and sophisticated statistical analysis tools required to derive multivariate QSAR models
  • Development and validation (according to the OECD principles) of QSARs, integrative models, expert systems and meta-tools.


    The eTOX project will be carried out by a Consortium comprising 25 organisations (13 pharmaceutical companies, 7 academic groups (including EMBL-EBI) and 5 SMEs) with complementary expertises. The total budget of the project is 13 million Euro and the project will last for five years.

    The website for the project is http://www.e-tox.net/

  • Comments

    PaulBo said…
    This is a very exciting project!

    Will the toxicity data be made publicly available during the course of the project?

    Popular posts from this blog

    New SureChEMBL announcement

    (Generated with DALL-E 3 ∙ 30 October 2023 at 1:48 pm) We have some very exciting news to report: the new SureChEMBL is now available! Hooray! What is SureChEMBL, you may ask. Good question! In our portfolio of chemical biology services, alongside our established database of bioactivity data for drug-like molecules ChEMBL , our dictionary of annotated small molecule entities ChEBI , and our compound cross-referencing system UniChem , we also deliver a database of annotated patents! Almost 10 years ago , EMBL-EBI acquired the SureChem system of chemically annotated patents and made this freely accessible in the public domain as SureChEMBL. Since then, our team has continued to maintain and deliver SureChEMBL. However, this has become increasingly challenging due to the complexities of the underlying codebase. We were awarded a Wellcome Trust grant in 2021 to completely overhaul SureChEMBL, with a new UI, backend infrastructure, and new f

    A python client for accessing ChEMBL web services

    Motivation The CheMBL Web Services provide simple reliable programmatic access to the data stored in ChEMBL database. RESTful API approaches are quite easy to master in most languages but still require writing a few lines of code. Additionally, it can be a challenging task to write a nontrivial application using REST without any examples. These factors were the motivation for us to write a small client library for accessing web services from Python. Why Python? We choose this language because Python has become extremely popular (and still growing in use) in scientific applications; there are several Open Source chemical toolkits available in this language, and so the wealth of ChEMBL resources and functionality of those toolkits can be easily combined. Moreover, Python is a very web-friendly language and we wanted to show how easy complex resource acquisition can be expressed in Python. Reinventing the wheel? There are already some libraries providing access to ChEMBL d

    LSH-based similarity search in MongoDB is faster than postgres cartridge.

    TL;DR: In his excellent blog post , Matt Swain described the implementation of compound similarity searches in MongoDB . Unfortunately, Matt's approach had suboptimal ( polynomial ) time complexity with respect to decreasing similarity thresholds, which renders unsuitable for production environments. In this article, we improve on the method by enhancing it with Locality Sensitive Hashing algorithm, which significantly reduces query time and outperforms RDKit PostgreSQL cartridge . myChEMBL 21 - NoSQL edition    Given that NoSQL technologies applied to computational chemistry and cheminformatics are gaining traction and popularity, we decided to include a taster in future myChEMBL releases. Two especially appealing technologies are Neo4j and MongoDB . The former is a graph database and the latter is a BSON document storage. We would like to provide IPython notebook -based tutorials explaining how to use this software to deal with common cheminformatics p

    Multi-task neural network on ChEMBL with PyTorch 1.0 and RDKit

      Update: KNIME protocol with the model available thanks to Greg Landrum. Update: New code to train the model and ONNX exported trained models available in github . The use and application of multi-task neural networks is growing rapidly in cheminformatics and drug discovery. Examples can be found in the following publications: - Deep Learning as an Opportunity in VirtualScreening - Massively Multitask Networks for Drug Discovery - Beyond the hype: deep neural networks outperform established methods using a ChEMBL bioactivity benchmark set But what is a multi-task neural network? In short, it's a kind of neural network architecture that can optimise multiple classification/regression problems at the same time while taking advantage of their shared description. This blogpost gives a great overview of their architecture. All networks in references above implement the hard parameter sharing approach. So, having a set of activities relating targets and molecules we can tra

    ChEMBL 26 Released

    We are pleased to announce the release of ChEMBL_26 This version of the database, prepared on 10/01/2020 contains: 2,425,876 compound records 1,950,765 compounds (of which 1,940,733 have mol files) 15,996,368 activities 1,221,311 assays 13,377 targets 76,076 documents You can query the ChEMBL 26 data online via the ChEMBL Interface and you can also download the data from the ChEMBL FTP site . Please see ChEMBL_26 release notes for full details of all changes in this release. Changes since the last release: * Deposited Data Sets: CO-ADD antimicrobial screening data: Two new data sets have been included from the Community for Open Access Drug Discovery (CO-ADD). These data sets are screening of the NIH NCI Natural Product Set III in the CO-ADD assays (src_id = 40, Document ChEMBL_ID = CHEMBL4296183, DOI = 10.6019/CHEMBL4296183) and screening of the NIH NCI Diversity Set V in the CO-ADD assays (src_id = 40, Document ChEMBL_ID = CHEMBL4296182, DOI = 10.601